Liraglutide still a ‘decent market’ despite Novo’s price moves: Siddharth Mittal, Biocon

Biocon CEO Siddharth Mittal outlines the company’s strategy in the competitive GLP-1 market. Focusing on liraglutide’s launch in the US and Europe, he highlights opportunities in emerging markets. While semaglutide is a longer-term play, Biocon is actively filing for approvals, anticipating launches in 2027.

© 2024 Investment-solutions.co | All Rights Reserved
Disclaimer: Investment-solutions.co offers evaluations, insights, and reports on financial markets and investment products. We do not provide brokerage services nor can we promise specific financial outcomes. Every investment carries risk, including the potential loss of invested capital. The material on this website is intended for informational use only and should not be interpreted as professional financial advice. Outcomes may differ, and it’s important to seek guidance from a licensed financial advisor before making any investment decisions.

Risk Warning
Trading in financial markets, including currencies, carries a high level of risk and may result in the loss of your capital. Price fluctuations may occur due to factors such as market volatility, regulatory updates, or political events. Past performance is not a reliable indicator of future results.

Content Usage Restrictions
No portion of this website or its materials may be copied, shared, or distributed in any manner without express written consent from Investment-solutions.co.

The information on this website does not constitute investment advice or a recommendation or a solicitation to engage in any investment activity. This website and its content are not intended for residents of the UAE, US, Canada, Australia, UK, Russia, North Korea, China, Japan, Hong Kong, Singapore and Iran.

Generated by Feedzy